Literature DB >> 30315442

Correlations between Body Mass Index, Plasma High-Sensitivity C-Reactive Protein and Lipids in Patients with Schizophrenia.

Ted Boozalis1, Sridevi Devaraj2,3, Olaoluwa O Okusaga4,5.   

Abstract

High prevalence of obesity in individuals with schizophrenia, associated with metabolic syndrome, leads to high rate of premature deaths from cardiovascular disease (CVD) in this population. Body mass index (BMI) and C-reactive protein (CRP) are correlated in the general population but this relationship has not been fully elucidated in patients with schizophrenia. We aimed to evaluate the correlation between BMI and CRP while relating both variables to plasma lipids in patients with schizophrenia. BMI, fasting high sensitivity CRP (hs-CRP), cotinine, and lipids were measured in 106 patients with schizophrenia (diagnosis confirmed with MINI). Pearson's and partial correlations (adjusting for age, sex, race, education and cotinine) between BMI, hs-CRP and lipids were calculated. Based on BMI, the patients were divided into normal-weight vs. overweight/obese and t-tests and linear regression were done to compare hs-CRP and lipids in the 2 groups. BMI positively correlated with hs-CRP (r = 0.29, p = 0.004). BMI and hs-CRP negatively correlated with HDL in the total sample (r = -0.29, p = 0.004; r = -0.37, p < 0.001 respectively). Furthermore, hs-CRP negatively correlated with HDL in overweight/obese patients (r = -0.41, p = 0.003), but not in normal-weight patients. hs-CRP and triglycerides were higher (1.62 ± 0.09 mg/L vs. 0.56 ± 0.08 mg/L, p < 0.001; 121.77 ± 8.96 mg/dL vs. 91.23 ± 6.52 mg/dL, p = 0.008 respectively) and HDL lower (39.55 ± 1.48 mg/dL vs. 50.68 ± 2.24 mg/dL, p < 0.001) in overweight/obese patients. Being overweight/obese is associated with increased inflammation and dyslipidemia in patients with schizophrenia. Effective interventions to prevent weight gain in schizophrenia are urgently needed.

Entities:  

Keywords:  BMI; Cardiovascular disease; Hs-CRP; Obese; Overweight; Plasma lipids; Schizophrenia

Mesh:

Substances:

Year:  2019        PMID: 30315442     DOI: 10.1007/s11126-018-9606-3

Source DB:  PubMed          Journal:  Psychiatr Q        ISSN: 0033-2720


  56 in total

1.  Correlation of CRP, fasting serum triglycerides and obesity as cardiovascular risk factors.

Authors:  Samar Firdous
Journal:  J Coll Physicians Surg Pak       Date:  2014-05       Impact factor: 0.711

2.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

3.  C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia.

Authors:  Mounir H Fawzi; Mohab M Fawzi; Maggie M Fawzi; Nagwa S Said
Journal:  Psychiatry Res       Date:  2011-05-31       Impact factor: 3.222

4.  Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.

Authors:  Christoph U Correll; Delbert G Robinson; Nina R Schooler; Mary F Brunette; Kim T Mueser; Robert A Rosenheck; Patricia Marcy; Jean Addington; Sue E Estroff; James Robinson; David L Penn; Susan Azrin; Amy Goldstein; Joanne Severe; Robert Heinssen; John M Kane
Journal:  JAMA Psychiatry       Date:  2014-12-01       Impact factor: 21.596

5.  Postprandial Monocyte Activation in Individuals With Metabolic Syndrome.

Authors:  Ilvira M Khan; Yashashwi Pokharel; Razvan T Dadu; Dorothy E Lewis; Ron C Hoogeveen; Huaizhu Wu; Christie M Ballantyne
Journal:  J Clin Endocrinol Metab       Date:  2016-08-30       Impact factor: 5.958

Review 6.  C-reactive protein levels in schizophrenia: a review and meta-analysis.

Authors:  Brian J Miller; Nick Culpepper; Mark H Rapaport
Journal:  Clin Schizophr Relat Psychoses       Date:  2014-01

Review 7.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

Authors:  D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

Review 8.  Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment.

Authors:  Adrian L Lopresti; Peter D Drummond
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-05-14       Impact factor: 5.067

Review 9.  The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia.

Authors:  Kyoung-Sae Na; Han-Yong Jung; Yong-Ku Kim
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-11-01       Impact factor: 5.067

Review 10.  The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment.

Authors:  Alex T Raben; Victoria S Marshe; Araba Chintoh; Ilona Gorbovskaya; Daniel J Müller; Margaret K Hahn
Journal:  Front Neurosci       Date:  2018-01-22       Impact factor: 4.677

View more
  2 in total

1.  Plasma soluble P-selectin correlates with triglycerides and nitrite in overweight/obese patients with schizophrenia.

Authors:  Katelynn A Bourassa; Teodor T Postolache; Aline Dagdag; Dietmar Fuchs; Olaoluwa O Okusaga
Journal:  Pteridines       Date:  2020-05-23       Impact factor: 0.581

2.  History of Suicide Attempts and COVID-19 Infection in Veterans with Schizophrenia or Schizoaffective Disorder: Moderating Effects of Age and Body Mass Index.

Authors:  Olaoluwa O Okusaga; Rachel L Kember; Gina M Peloso; Roseann E Peterson; Mariana Vujkovic; Brian G Mitchell; Jared Bernard; Annette Walder; Tim B Bigdeli
Journal:  Complex Psychiatry       Date:  2021-12-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.